07 December 2017
The CLINUVEL team is looking with much optimism and energy to the start of 2018. I believe the year ahead is one where the Company will make great strides on various fronts: research, product development, distribution, and restructuring of the Group of companies. We all eagerly await the day our teams can supply SCENESSE® (afamelanotide 16mg) to US erythropoietic protoporphyria (EPP) patients who endlessly request updates on progress. That very day will be the epitome of CLINUVEL’s lengthy crusade, and a most fulfilling professional moment.